Vieira Andreia Salezze, Beijamini Vanessa, Melchiors Ana Carolina
Center of North Espírito Santo, Federal University of Espírito Santo, São Mateus, Brazil.
An Bras Dermatol. 2012 May-Jun;87(3):382-7. doi: 10.1590/s0365-05962012000300005.
Isotretinoin has been used to treat the most severe cases of acne; however, it may provoke adverse events in mucocutaneous and hepatic tissues, lead to alterations in lipid levels and cause teratogenicity.
The objective of this study was to evaluate the profile of changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and triglyceride levels in patients who had been treated with oral isotretinoin dispensed by the São Mateus/ES pharmacy for special drugs.
A retrospective, observational, longitudinal study was conducted by carrying out a secondary analysis of each patient's data.
Of the 130 patients who received isotretinoin between January and December 2009, only 70 were actually treated for 3 months or more and handed in the results of their laboratory tests. Of these 70 patients, 39 (55.7%) were female. The mean age of the women (23.9 years) was higher than the mean age of the men (20.1 years). There was a statistically significant increase in the levels of triglycerides (87.01 ± 48.25 versus 105.32 ± 48.76 mg/dL), AST (20.44 ± 6.26 versus 24.38 ± 11.92 U/L) and ALT (18.24 ± 8.31 versus 23.34 ± 20.03 U/L) performed prior to and 3 months or more after oral isotretinoin treatment. After treatment with oral isotretinoin, triglyceride levels had increased beyond the normal range in 11% of the patients, while 8.6% had elevated AST levels and 7.3% had increased ALT levels.
The results in this population show that the use of oral isotretinoin for the treatment of acne may result in altered triglyceride, AST and ALT levels. These findings are in accordance with data published previously in the scientific literature, confirming the need to monitor these patients.
异维A酸已被用于治疗最严重的痤疮病例;然而,它可能引发皮肤黏膜和肝脏组织的不良事件,导致血脂水平改变并引起致畸性。
本研究的目的是评估由圣马特乌斯/ES特殊药品药房配发口服异维A酸治疗的患者中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和甘油三酯水平的变化情况。
通过对每位患者的数据进行二次分析,开展了一项回顾性、观察性纵向研究。
在2009年1月至12月期间接受异维A酸治疗的130例患者中,只有70例实际接受治疗3个月或更长时间并提交了实验室检查结果。在这70例患者中,39例(55.7%)为女性。女性的平均年龄(23.9岁)高于男性的平均年龄(20.1岁)。口服异维A酸治疗前及治疗3个月或更长时间后检测的甘油三酯水平(87.01±48.25对105.32±48.76mg/dL)、AST水平(20.44±6.26对24.38±11.92U/L)和ALT水平(18.24±8.31对23.34±20.03U/L)有统计学意义的升高。口服异维A酸治疗后,11%的患者甘油三酯水平升高超出正常范围,而8.6%的患者AST水平升高,7.3%的患者ALT水平升高。
该人群的结果表明,口服异维A酸治疗痤疮可能导致甘油三酯、AST和ALT水平改变。这些发现与科学文献中先前发表的数据一致,证实了对这些患者进行监测的必要性。